Navigation Links
Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
Date:7/31/2013

t as may be required by law.

Statement Required by the Irish Takeover RulesThe directors of Actavis accept responsibility for the information contained in this announcement other than that relating to Warner Chilcott and its Associates and the directors of Warner Chilcott and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Actavis (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

The directors of Warner Chilcott accept responsibility for the information contained in this announcement relating to Warner Chilcott and its Associates and the directors of Warner Chilcott and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Warner Chilcott (who have taken all reasonable care to ensure such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

BofA Merrill Lynch and Greenhill & Co. are acting exclusively for Actavis and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Actavis for providing the protections afforded to clients of BofA Merrill Lynch or Greenhill & Co and for providing advice in relation to the acquisition of Warner Chilcott, the contents of this announcement or any transaction or arrangement referred to herein.

Deutsche Bank Securities Inc. is acting for Warner Chilcott as financial advisor and is not acting as financial advisor to anyone else in connection with the matters referred to in this announcem
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
10. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
11. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NYSE: HSP ), a global specialty pharmaceutical ... present at two upcoming conferences: , Raymond ... 8, 2011 (Tuesday) – Orlando, Fla.  9:15 a.m. Eastern time ... March 16, 2011 (Wednesday) – Miami, ...
... 2011 Dynatronics Corporation (Nasdaq: DYNT ) today ... 2010. Sales for the quarter ended December 31, ... December 31, 2009. Sales for the six months ended December ... period of the prior year. Net income ...
Cached Medicine Technology:Dynatronics Announces Fiscal Second Quarter Results 2Dynatronics Announces Fiscal Second Quarter Results 3Dynatronics Announces Fiscal Second Quarter Results 4
(Date:4/17/2014)... new study has found that India,s shocking rates of ... farmers who are clinging to tiny smallholdings less ... crops, such as cotton and coffee, that are highly ... a range of previous case studies that point to ... following the ,liberalisation, of the nation,s economy during the ...
(Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... of the embryo. It begins as a glob of identical ... become the cells of our lungs, muscles, nerves and all ... a feat of reverse tissue engineering, Stanford University researchers have ... cells to proliferate and transform into all of the specialized ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... involved in cancer, aging , , MONDAY, Sept. 1 (HealthDay ... active region of telomerase, an enzyme involved in both ... repeats of a short DNA sequence to the ends ... damage and loss of genetic information during cell division. ...
... appear to be at higher risk for psychiatric ... children, according to a report in the September ... one of the JAMA/Archives journals. In addition, low-birth-weight ... to have attention problems than suburban low-birth-weight children. ...
... the East coast distribute formula sample packs to new ... concerned about the potential for distributing these packs to ... September issue of Archives of Pediatrics & Adolescent ... practice is changing significantly. , "Packaged as smart diaper ...
... found it predicted outcome months after patient went home ... who sleep during the day while in rehabilitation have ... study, which was expected to be published in the ... the sleeping patterns and other predictors of recovery (e.g., ...
... drug from a biodegradable polymer , , MONDAY, Sept. 1 ... artery-opening, drug-eluting stents appears equally effective as older models ... study shows. , Stents are tiny mesh tubes inserted ... medicines that help prevent reclosure. The latest form of ...
... of a former U.S. soldier whose traumatic brain injuries (TBIs) were ... years after his discharge. The soldier, who suffered several concussions during ... and hearing/visibility issues on a daily basis. , ... ...
Cached Medicine News:Health News:Secrets of Telomerase Revealed 2Health News:Study examines relationship between low birth weight and psychiatric problems in children 2Health News:Hospitals provide formula sample packs while medical organizations encourage breastfeeding 2Health News:Daytime Sleeping Linked to Poor Recovery in Older Patients 2Health News:New Type of Stent Appears Safe, Effective 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 3Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 4
Inquire...
Spectrafuge 24D High speed, digital microcentrifuge. Precision control with digital display. Easy access 24-place rotor. Set and view speed in rpm or rcf. Quiet and cool running. StripSpin adapter fo...
... More Separating Power , Micromax produces ... 15,000 rpm on 24 (1.5-2.0 mL) samples or ... Because Micromax's brushless motor is designed for longevity ... time and money. In addition, all controls are ...
... two centrifuges -- the world's most popular ... in one reliable, quiet, compact unit. It ... two separate centrifuges!, For your microcentrifuge needs, ... supplies you with the MicroMB centrifuge, microcentrifuge ...
Medicine Products: